- Are we justified to classify patients with two unrelated clones with del(5q) and trisomy 8 as a subgroup of myelodysplastic syndrome of the type of 5q-syndrome?2014 | First Faculty of Medicine
- MiRNA expression profilig in 5q-syndrome patiens treated with lenalidomidePublication without faculty affiliation
- Immunomodulation therapy - lenalidomide in the treatment of myelodysplastic syndrome in low-risk groups with deletion of the long arm of chromosome 52013 | First Faculty of Medicine
- Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q-syndrome and in Diamond-Blackfan anemia2013 | First Faculty of Medicine
- Are Fli1, EKLF, PU.1, HDM2 and TP53 factors implicated in refractory anemia and megakaryopoiesis in 5q- syndromePublication without faculty affiliation
- Differential Expression of MicroRNAs in CD34+ Cells of 5q- Syndrome2011 | First Faculty of Medicine
- Case report: (non)chelated, poly-transfused patient with 5q minus syndrome2015 | First Faculty of Medicine
- Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome2015 | First Faculty of Medicine
- The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatmentPublication without faculty affiliation
- Experience with chelatation therapy in patients with myelodysplastic syndrome2011 | Faculty of Medicine in Hradec Králové
- The benefit of luspatercept in the treatment of low‑risk myelodysplastic syndrome – case report2023 | First Faculty of Medicine
